Cardiovascular effects of carbamazepine toxicity

Apfelbaum JD, Caravati EM, Kerns WP, Bossart PJ, Larsen G

Annals of emergency medicine, 1995

Abstract

STUDY OBJECTIVE: To evaluate the cardiovascular effects of carbamazepine in patients presenting to the emergency department.

DESIGN: A retrospective case series from February 1, 1985, to July 30, 1993.

SETTING: Six urban EDs.

PARTICIPANTS: Seventy-two adult and pediatric patients with serum carbamazepine concentrations greater than 12 micrograms/mL and concurrent 12-lead ECGs.

RESULTS: The mean carbamazepine level was 24 micrograms/mL (range, 12.6 to 55 micrograms/mL). Minor ECG abnormalities were noted but no clinically significant arrhythmias were found. No correlation was found between carbamazepine concentration and heart rate or PR, QRS, or corrected QT intervals. Four adult patients had transient hypotension.

CONCLUSION: Clinically significant cardiovascular toxicity occurs rarely in patients with toxic carbamazepine concentrations. ECG findings do not correlate with serum carbamazepine concentration.

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

• DOI
• PubMed
• Publisher page

Related studies

• The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices Molecular & Cellular Proteomics, 2011
• The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities Proceedings of the National Academy of Sciences, 2000
• In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling British Journal of Pharmacology, 2007
• In silico prediction of splice-altering single nucleotide variants in the human genome Nucleic Acids Research, 2014
• In silico clinical trials: how computer simulation will transform the biomedical industry International Journal of Clinical Trials, 2016
• In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design Nature Communications, 2018

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free